echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Gospel for patients with chronic skin and respiratory diseases: FDA approves Dupilumab's 300mg pre-filled pen.

    Gospel for patients with chronic skin and respiratory diseases: FDA approves Dupilumab's 300mg pre-filled pen.

    • Last Update: 2020-10-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, the FDA has approved Dupilumab's 300mg single-dose pre-fill pen for all Dupixent adaptations in patients 12 years of age and older, including epithelial dermatitis, asthma and chronic nasal sinusitis with nasal dipherone (CRSwNP).
    the new pre-filled pen will provide patients with a more convenient way to manage Dupixent.
    Bill Sibold, vice president of Sanofi, said: "Dupixent prefill pens are developed to meet the needs of patients and provide the latest technical support, including audio-visual tips."
    the 300mg pre-fill pen, which is expected to be available in the U.S. in the third quarter of 2020, features hidden needles and single-press auto-injection, as well as visual and audio feedback to help patients manage themselves. "The treatment of chronic inflammatory diseases, such as adiotic dermatitis, asthma and chronic nasal-sinusitis, is complex and burdens on patients," said George D. Yancopoulos, M.D., founder of
    Regeneration.
    Dupixent pre-filled pen will make it easier for patients to inject."
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.